MedRx Co., Ltd (TYO:4586)

Market Cap	3.13B
Revenue (ttm)	257.00M
Net Income (ttm)	-806.00M
Shares Out	47.50M
EPS (ttm)	-18.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	783,800
Average Volume	1,368,060
Open	64.00
Previous Close	64.00
Day's Range	64.00 - 68.00
52-Week Range	55.00 - 199.00
Beta	1.02
RSI	45.36
Earnings Date	May 9, 2025

About MedRx

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 22
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4586

Financial Performance

In 2024, MedRx's revenue was 257.00 million, an increase of 786.21% compared to the previous year's 29.00 million. Losses were -806.00 million, -13.52% less than in 2023.